- ASSISTANT PROFESSOR Psychiatry
- ASSISTANT PROFESSOR Neuroscience
Psychiatry, American Board of Psychiatry and Neurology
Mount Sinai Hospital
Dr. James Murrough is a Board-certified psychiatrist and a research fellow in the Mount Sinai School of Medicine Mood and Anxiety Disorders Program within the Department of Psychiatry. Dr. Murrough conducts experimental therapeutics and clinical neuroscience research in major depression, among other mood and anxiety disorders. Current focuses of his research include investigations of ketamine in treatment-resistant depression and brain mechanisms of antidepressant response measured using functional neuroimaging.Key Words: depression, bipolar disorder, posttraumatic stress disorder, psychopharmacology, antidepressants, functional neuroimaging
Financial & Billing Information
Please direct any detailed billing or financial inquires to the Mount Sinai Psychiatry billing customer service number at 212-659-8752.
Murrough JW, Mathew SJ. Overcoming antidepressant treatment resistance: focus on glutamate. Modern Trends in Pharmacopsychiatry; 27.
Murrough JW, Mathew SJ. Neurochemical Imaging in Anxiety Disorders. Neuropsychiatric Imaging;.
Murrough JW, Mao X, Collins KA, Kelly C, Andrade G, Nestadt P, Levine SM, Mathew SJ, Shungu DC. Increased Ventricular Cerebrospinal Fluid Lactate in Chronic Fatigue Syndrome. Part II: Comparison with Major Depressive Disorder by 1H MRS at 3.0 Tesla. NMR Biomedicine 2010; 23: 643-650.
Murrough JW, Henry S, Hu J, Gallezot JD, Planeta-Wilson B, Neumaier JF, Neumeister A. Reduced ventral striatal/ventral pallidal serotonin(1B) receptor binding potential in major depressive disorder. Psychopharmacology (Berl) 2010 May;.
aan het Rot M, Collins KA, Murrough JW, Perez A, Reich DL, Charney DS, Mathew SJ. Safety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression. Biol Psychiatry 2010; 67: 139-145.
Mathew SJ, Murrough JW, aan het Rot M, Collins KA, Garakani A, Reich DL, Charney DS. Riluzole for Relapse Prevention Following Intravenous Ketamine in Treatment-Resistant Depression: A Pilot Randomized, Placebo-Controlled Study. Int J Neuropsychopharm 2010; 13: 71-82.
New AS, Fan J, Murrough JW, Liu X, Liebman RE, Guise KG, Tang CY, Charney DS. An Functional Magnetic Resonance Imaging Study of Deliberate Emotion Regulation in Resilience and Posttraumatic Stress Disorder. Biol. Psychiatry 2009; 66: 656-664.
Price RB, Shungu DC, Mao X, Nestadt P, Kelly C, Collins KA, Murrough JW, Charney DS, Mathew SJ. Amino Acid Neurotransmitters in the Occipital and Anterior Cingulate Cortices: Relationship to Treatment-Resistance in Major Depressive Disorder. Biol Psychiatry 2009; 65: 792-800.
Epstein J, Pan H, Kocsis JH, Yang Y, Butler T, Chusid J, Hochberg H, Murrough J, Strohmayer E, Stern E, Silbersweig DA. Lack of Ventral Striatal Response to Positive Stimuli in Depressed Versus Normal Subjects. Am J Psychiatry 2006; 163: 1784-1790.
Murrough JW, Boss-Williams KA, Emery MS, Bonsall RW, Weiss JM. Depletion of Brain Norepinephrine Does Not Reduce Spontaneous Ambulatory Activity of Rats in the Home Cage. Brain Res 2000; 883: 125-130.
- Intranasal (IN) Ketamine in Treatment Resistant Depression (TRD)
- Intravenous (IV) Ketamine in Treatment-Resistant Bipolar Depression (TRBD)
- Intranasal Administration of Neuropeptide Y in PTSD
- Targeting the NMDA Glutamate Receptor as a Novel Antidepressant Strategy: A Pilot Clinical Trial of Nuedexta in Treatment-Resistant Major Depression
- A double-blind, randomized, placebo-controlled, parallel group, dose frequency study of ketamine in subjects with treatment-resistant depression
- Ketamine Plus Lithium as a Novel Pharmacotherapeutic Strategy in Treatment Resistant Depression
- An fMRI Study of Ketamine in Treatment-Resistant Depression
- A Proof-Of-Concept Clinical Trial of a Novel KCNQ Potentiator in Major Depressive Disorder
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Murrough during 2014 and/or 2015. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
- Impel NeuroPharma; ProPhase, LLC
Scientific Advisory Board:
- Genentech, Inc.; Janssen Pharmaceuticals, Inc.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.
Atran Berg Laboratory Building Floor Level E (Ground Floo Room ABE 39
1428 Madison Avenue
New York, NY 10029
1428 Madison Avenue
E Level Room ABE-39
New York, NY 10029
- Monday 9:00am - 5:00pm
- Tuesday 9:00am - 5:00pm
- Wednesday 9:00am - 5:00pm
- Thursday 9:00am - 5:00pm
- Friday 9:00am - 5:00pm
- Master Card
- American Express
- Personal Check
- Credit Card (Other)